期刊
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
卷 46, 期 3, 页码 627-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2017.05.015
关键词
Crohn's disease; Jak inhibitor; Filgotinib; TGF-beta; SMAD7; Mongersen; Sphingosine-1-phosphate receptor; Ozanimod
资金
- Abbvie
- Takeda
- Janssen
- MSD
- Ferring
- Dr. Falk Pharma
- Hospira
- Pfizer
- Tillots
There is an ongoing, unmet need for effective therapies for Crohn's disease. Treatments for Crohn's disease continue to evolve from the traditional biologics to novel small molecules, with targeted mechanisms directed toward pathways that are dysregulated in Crohn's disease. There are multiple emerging mechanisms of action, including Janus kinase inhibition, Smad7 inhibition, and sphingosine-1-phosphate receptor modulators, that are administered as oral medications, and small molecules represent the next generation of therapies for Crohn's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据